Eisai, BioArctic Neuroscience Ink Alzheimer's Agreement

December 4, 2007

Japanese drugmaker Eisai and Sweden’s BioArctic Neuroscience have signed a license agreement for BAN2401, a novel humanized monoclonal antibody being developed as a treatment for Alzheimer’s disease.

Under the agreement, Eisai will obtain global rights to develop and market BAN2401, which is in preclinical development, Eisai said.

The drug’s development comes as a result of a 2005 research alliance between Eisai and BioArctic.